List of Excipients in Branded Drug DEXEDRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	DEXEDRINE	dextroamphetamine sulfate	64896-673	CETYL ALCOHOL
Amneal Pharmaceuticals LLC	DEXEDRINE	dextroamphetamine sulfate	64896-673	D&C YELLOW NO. 10
Amneal Pharmaceuticals LLC	DEXEDRINE	dextroamphetamine sulfate	64896-673	DIBUTYL SEBACATE
Amneal Pharmaceuticals LLC	DEXEDRINE	dextroamphetamine sulfate	64896-673	ETHYLCELLULOSES
Amneal Pharmaceuticals LLC	DEXEDRINE	dextroamphetamine sulfate	64896-673	FD&C BLUE NO. 1

DEXEDRINE Excipient Strategy and Commercial Opportunities in Dextroamphetamine Products

Last updated: August 14, 2026

DEXEDRINE is an immediate-release and sustained-release dextroamphetamine sulfate product used primarily for attention-deficit/hyperactivity disorder and narcolepsy. Its commercial opportunity is driven less by new-molecule patent protection than by formulation performance, controlled-substance supply reliability, pediatric acceptability, abuse-deterrence positioning, and differentiated generic or 505(b)(2) products.

The strongest excipient opportunities are in sustained-release multiparticulates, taste-masked pediatric formats, lower-allergen formulations, rapid-disintegration tablets, and manufacturing platforms that reduce variability in amphetamine release. The principal constraints are Schedule II controls, stimulant labeling requirements, FDA scrutiny of bioequivalence, and limited ability to make therapeutic claims based only on excipient changes.

What is DEXEDRINE and which formulations are marketed?

DEXEDRINE contains dextroamphetamine sulfate, the dextrorotatory sulfate salt of amphetamine. The product has been marketed in two principal dosage-form families:

Product	Dosage form	Typical strengths	Release profile	Primary commercial role
DEXEDRINE	Tablet	5 mg	Immediate release	Flexible dose titration and lower-cost stimulant therapy
DEXEDRINE SPANSULE	Extended-release capsule	5 mg, 10 mg, 15 mg	Sustained release	Reduced dosing frequency and prolonged exposure

The FDA labeling identifies DEXEDRINE tablets as containing dextroamphetamine sulfate in an immediate-release tablet and DEXEDRINE SPANSULE as a sustained-release capsule dosage form.[1] The products are Schedule II controlled substances under the Controlled Substances Act.[2]

Dextroamphetamine products compete with mixed amphetamine salts, lisdexamfetamine, methylphenidate products, and nonstimulant ADHD therapies. DEXEDRINE's commercial differentiation is based on the active moiety, dosing flexibility, and sustained-release delivery rather than on a recent composition-of-matter patent.

What excipients are used in DEXEDRINE tablets and DEXEDRINE SPANSULE?

The immediate-release tablet and sustained-release capsule require different excipient strategies.

Immediate-release tablet excipients

The tablet platform generally uses conventional oral solid-dose excipients, including a diluent, disintegrant, lubricant, and tablet-processing aids. Public product labeling identifies excipients such as lactose, corn starch, and magnesium stearate for the tablet presentation.[1]

The formulation objectives are:

• Rapid tablet breakup and dissolution.
• Consistent low-dose content uniformity.
• Minimal impact on dextroamphetamine sulfate dissolution.
• Adequate mechanical strength for packaging and handling.
• Low manufacturing complexity and cost.

For a 5 mg tablet, the active pharmaceutical ingredient represents a relatively small proportion of total tablet mass. Excipient selection therefore affects blend uniformity, dose accuracy, tablet weight, hardness, and dissolution. Direct compression may reduce processing steps, but wet granulation can improve flow and content uniformity when the API has poor flow or segregation risk.

Lactose creates a potential commercial limitation for patients avoiding milk-derived excipients or for manufacturers seeking a fully lactose-free product. A lactose-free alternative using microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient could support product differentiation, provided dissolution and bioequivalence remain acceptable.

Sustained-release capsule excipients

DEXEDRINE SPANSULE uses a multiparticulate sustained-release design. The product contains coated particles or beads within a hard gelatin capsule. The release system relies on a combination of inert cores, drug layering, polymeric coating, and pore-control or processing excipients.[1]

A typical multiparticulate platform may use:

• Sugar spheres or other inert starter cores.
• Povidone or another binder for drug layering.
• Ethylcellulose or a comparable water-insoluble polymer for controlled release.
• Talc or other anti-tacking materials.
• Gelatin capsule shells.
• Colorants and opacifiers where required.

The critical quality attributes are coating weight gain, polymer uniformity, bead-size distribution, capsule fill weight, assay, content uniformity, and dissolution across the full sampling period. Changes in polymer grade, coating thickness, plasticizer concentration, bead diameter, or capsule fill can alter the release profile.

Multiparticulates can reduce the risk of dose dumping compared with a single-unit matrix system, but that advantage depends on the actual formulation and in vitro and in vivo performance. Any product that uses a materially different release mechanism must be evaluated against FDA's modified-release guidance and applicable ANDA or 505(b)(2) requirements.[3]

What excipient strategy offers the strongest commercial opportunity?

The highest-value strategy is to use excipients to solve a clinically visible administration problem without changing the approved therapeutic profile.

Lactose-free and simplified formulations

A lactose-free immediate-release tablet could target patients with excipient restrictions, pharmacy substitution needs, and institutional formularies that prefer simplified inactive-ingredient profiles. The opportunity is commercially credible but limited by the availability of existing generic dextroamphetamine tablets.

A successful formulation would need to preserve:

• Immediate dissolution.
• Dose uniformity at 5 mg.
• Tablet robustness.
• Comparable stability.
• Acceptable tablet size and swallowability.

A lactose-free product may also reduce procurement friction for hospitals, pediatric practices, and specialty pharmacies that maintain excipient-screening protocols.

Pediatric-friendly dosage forms

Children are a major user population for dextroamphetamine products. Commercial opportunities include:

• Sprinkle capsules containing coated beads.
• Orally disintegrating tablets.
• Chewable tablets.
• Taste-masked mini-tablets.
• Oral liquids or suspensions.
• Capsules that can be opened and administered with soft food, if supported by labeling and product performance.

Taste masking is technically important because amphetamine salts can produce a strong unpleasant taste. Ion-exchange resins, polymer coatings, lipid barriers, sweeteners, flavors, and pH-modifying systems are potential approaches. The main risk is that taste-masking coatings can delay or distort release, particularly in an immediate-release product.

A pediatric liquid would create a dose-flexibility advantage, but it would also introduce stability, preservative, microbial-control, packaging, and diversion-control challenges. A unit-dose oral liquid or metered dispenser could provide commercial differentiation, although Schedule II distribution and dispensing controls would remain.

Extended-release bead optimization

The most defensible formulation opportunity is an improved sustained-release bead system. Potential targets include:

• More consistent initial release.
• Reduced peak-to-trough fluctuation.
• Lower sensitivity to gastric pH.
• Lower food-effect variability.
• Improved bead robustness during capsule opening.
• Better release reproducibility across manufacturing sites.
• Lower coating-material consumption.

A new bead architecture may support an ANDA if it is pharmaceutically equivalent and bioequivalent to the reference product. A clinically differentiated release profile would more likely require a 505(b)(2) pathway, with additional clinical and regulatory work.

Abuse-deterrence excipients

Abuse-deterrent formulations are a potential strategic area, but excipient changes alone do not establish abuse-deterrent labeling. FDA's abuse-deterrent framework evaluates resistance to manipulation, extraction, insufflation, injection, and other abuse routes.[4]

Potential technologies include:

• Crush-resistant matrices.
• Gelling polymers.
• Irritant or aversive excipients.
• Sequestration systems.
• Coatings that resist solvent extraction.
• Multiparticulate systems that are difficult to isolate or concentrate.

For DEXEDRINE, abuse-deterrence claims would face a high evidentiary threshold. The product is already a Schedule II stimulant, and manufacturers would need to demonstrate meaningful resistance to abuse modes relevant to amphetamine products. A commercial product could still use tamper-resistant packaging without pursuing formal abuse-deterrent labeling.

What patents protect DEXEDRINE formulations?

The original dextroamphetamine molecule and early DEXEDRINE products are not expected to have meaningful surviving composition-of-matter exclusivity. The commercial IP question is formulation-specific.

Potentially relevant patent categories include:

IP category	Commercial relevance	Likely protection target
Multiparticulate release patents	High	Polymer layers, bead architecture, release windows
Taste-masking patents	Moderate	Coatings, resin complexes, pediatric dosage forms
Abuse-deterrence patents	Moderate to high	Sequestration, crush resistance, extraction resistance
Capsule-opening patents	Moderate	Food-sprinkle administration and bead integrity
Manufacturing patents	Moderate	Drug layering, coating, curing, and scale-up controls
Packaging patents	Low to moderate	Unit-dose, child-resistant, diversion-resistant packaging
Method-of-use patents	Limited	Dosing regimens or specific patient populations

A formulation patent must be evaluated claim by claim. The existence of a patent directed to an extended-release amphetamine product does not establish infringement by every sustained-release dextroamphetamine formulation.

The Orange Book is the primary source for patents and exclusivity tied to approved drug products. FDA's Orange Book should be reviewed by NDA number and product presentation for current patent listings, exclusivity codes, and any patent delisting activity.[5] Patent-family review should then include U.S. continuation, divisional, terminal-disclaimer, and foreign counterpart records.

When does DEXEDRINE lose exclusivity?

DEXEDRINE's principal market protection is regulatory and commercial rather than current molecule-level patent exclusivity.

Protection type	Assessment
New chemical entity exclusivity	Historical period has expired
Composition-of-matter patent	No material current protection expected for the old active ingredient
Original product exclusivity	Expired
Formulation patents	Must be assessed by product and patent family
Method-of-use patents	Must be assessed through current Orange Book listings
Generic competition	Established for dextroamphetamine sulfate products
Brand protection	Primarily prescribing, supply, manufacturing, and distribution based

A generic manufacturer can generally pursue an ANDA for an approved reference product once applicable patents and exclusivity barriers have expired or are addressed. For listed patents, an ANDA applicant may submit Paragraph IV certifications under the Hatch-Waxman Act.[6]

Because DEXEDRINE has an old active ingredient and established generic competition, the core question is not whether the molecule has exclusivity. It is whether a particular sustained-release, pediatric, or abuse-deterrent formulation has enforceable claims and whether the proposed product is therapeutically and pharmaceutically equivalent.

Which companies are challenging or competing with DEXEDRINE?

Competition comes from both dextroamphetamine generics and alternative stimulant products.

Direct competitors

Direct competition includes generic dextroamphetamine sulfate tablets and sustained-release capsules. Depending on market availability, suppliers may include specialty generic manufacturers and established U.S. oral-solid-dose companies. Product availability can change because of controlled-substance quotas, API supply, manufacturing interruptions, and pharmacy purchasing decisions.

Therapeutic competitors

Product class	Examples	Competitive advantage
Mixed amphetamine salts	Immediate-release and extended-release products	Broad prescriber familiarity and multiple dosage options
Lisdexamfetamine	Vyvanse and generics	Prodrug design and once-daily positioning
Methylphenidate	Immediate-release and extended-release products	Large established treatment base
Atomoxetine	Strattera and generics	Nonstimulant option
Guanfacine or clonidine	Immediate-release and extended-release products	Nonstimulant and adjunctive use

Dextroamphetamine can be attractive where prescribers want a single amphetamine isomer, flexible titration, or a lower-cost alternative. Its market position is weaker where once-daily convenience, broad pediatric dosage flexibility, or a nonstimulant treatment profile dominates prescribing decisions.

What FDA regulatory pathway applies to a new DEXEDRINE excipient formulation?

The regulatory pathway depends on whether the product remains pharmaceutically equivalent and bioequivalent to the reference listed drug.

ANDA pathway

An ANDA is the most efficient route for a generic immediate-release or sustained-release product that matches the reference product's dosage form, strength, route, quality attributes, and therapeutic performance. Excipient differences are permitted when they do not create a safety, efficacy, or performance concern.

For an extended-release product, the applicant may need:

• Comparative dissolution testing.
• Fed and fasting pharmacokinetic studies.
• Partial or full replicate study designs where applicable.
• Alcohol-dose-dumping assessment.
• Comparative impurity and stability data.
• Device or capsule-opening studies for special administration instructions.

505(b)(2) pathway

A 505(b)(2) application may be appropriate when the product relies partly on existing FDA findings but introduces a meaningful change, such as:

• A new liquid dosage form.
• A clinically distinct release profile.
• A novel abuse-deterrent mechanism.
• A different route or administration method.
• A new pediatric delivery system.
• A new dosing regimen supported by additional data.

A 505(b)(2) applicant must evaluate listed patents and submit the applicable certifications. If an Orange Book-listed patent is challenged, a Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[6]

What patent litigation and Paragraph IV risks exist?

The principal litigation risk is concentrated in later-generation formulations rather than conventional immediate-release tablets.

Immediate-release tablet risk

A standard 5 mg dextroamphetamine sulfate tablet generally has a low formulation-barrier profile. Litigation risk would depend on an unexpired patent covering a specific excipient combination, manufacturing process, tablet architecture, or method of use.

Sustained-release risk

The risk is higher for extended-release capsules because release-controlling polymers and multiparticulate manufacturing processes can be claimed in multiple ways. A competitor may face:

• Composition claims directed to coated beads.
• Process claims directed to drug layering or curing.
• Dissolution-profile claims.
• Capsule-opening or sprinkle-administration claims.
• Method claims covering once-daily administration.

A Paragraph IV challenge can create litigation even where the active ingredient is old. The commercial value of a formulation patent depends on claim breadth, prosecution history, infringement evidence, patent-term adjustment, terminal disclaimers, and the number of non-infringing design-arounds.

How strong is the DEXEDRINE patent estate?

The DEXEDRINE patent estate is likely weak for the basic immediate-release product and potentially stronger for engineered sustained-release or pediatric formulations.

Product concept	Patent strength	Regulatory complexity	Commercial attractiveness
Conventional 5 mg tablet	Low	Low	Low to moderate
Lactose-free tablet	Low to moderate	Low to moderate	Moderate
Taste-masked pediatric tablet	Moderate	Moderate	Moderate to high
Sprinkle sustained-release capsule	Moderate to high	High	High
Novel bead-based extended release	Moderate to high	High	High
Abuse-deterrent formulation	High if claims are valid	Very high	Selective
Oral liquid	Moderate	Moderate to high	Moderate
Diversion-resistant packaging	Low to moderate	Moderate	Moderate

A strong estate would require claims that cover the product as sold, not only a narrow manufacturing condition. Broad claims directed to a release profile may be valuable, but they are vulnerable to validity and enablement challenges if the specification does not support the full scope.

What manufacturing and intellectual-property barriers affect commercialization?

The main barriers are process control and controlled-substance compliance.

Manufacturing barriers

Extended-release bead products require precise control of:

• API layering uniformity.
• Coating weight gain.
• Polymer dispersion.
• Drying and curing conditions.
• Bead-size distribution.
• Capsule fill accuracy.
• Dissolution at multiple time points.
• Scale-up equivalence between sites.

A formulation that performs well at laboratory scale may show altered release after commercial scale-up because of changes in spray rate, bed temperature, atomization, or coating efficiency.

Controlled-substance barriers

Manufacturers must manage DEA registration, quota allocation, inventory controls, suspicious-order monitoring, recordkeeping, and secure distribution. These obligations can limit the practical value of a low-cost formulation if the company cannot secure reliable API and production capacity.[2]

A product with two qualified API sources and a validated second manufacturing site may have greater commercial value than a marginally differentiated tablet with a single-source supply chain.

What licensing deals and partnership opportunities exist?

Publicly disclosed licensing opportunities specific to DEXEDRINE may be limited. The most practical transaction structures are platform-based rather than brand-specific.

Potential deal targets include:

• A generic manufacturer seeking a differentiated dextroamphetamine product.
• A specialty pharmaceutical company with Schedule II infrastructure.
• A pediatric drug-delivery company with taste-masking technology.
• A controlled-release coating supplier.
• A contract development and manufacturing organization with multiparticulate capability.
• A company holding abuse-deterrence IP.

The most attractive licensing asset would combine a defensible formulation patent, demonstrated bioequivalence or clinical performance, reliable API sourcing, and an established controlled-substance commercial channel. A formulation patent without manufacturing reproducibility has limited transaction value.

What generic launch scenarios exist for DEXEDRINE?

Scenario 1: Conventional tablet launch

This is the lowest-risk pathway. A manufacturer launches a bioequivalent immediate-release tablet using standard excipients. Price competition is likely intense, and differentiation depends on supply reliability, wholesaler access, and pharmacy contracting.

Scenario 2: Lactose-free or low-excipient launch

A lactose-free product could command modest preference among selected patients and institutions. The product would need a clear inactive-ingredient profile and consistent availability.

Scenario 3: Pediatric sprinkle or taste-masked launch

This has greater differentiation and may support specialty-pharmacy distribution. The regulatory burden increases because administration instructions, palatability, bead integrity, and food compatibility must be demonstrated.

Scenario 4: Novel extended-release launch

This offers the highest commercial upside but faces the greatest bioequivalence, patent, and manufacturing risks. The product must compete against established once-daily amphetamine and methylphenidate products, not only DEXEDRINE SPANSULE.

Scenario 5: Abuse-deterrent product

This could support premium pricing or institutional interest, but development costs and evidentiary requirements are substantial. The market may not reward the investment unless the product delivers a clear reduction in misuse or diversion risk.

How does DEXEDRINE compare with competing amphetamine products?

Attribute	DEXEDRINE	Mixed amphetamine salts	Lisdexamfetamine
Active ingredient	Dextroamphetamine sulfate	Multiple amphetamine salts	Dextroamphetamine prodrug
Immediate-release option	Yes	Yes	No
Extended-release option	Yes	Yes	Yes
Pediatric flexibility	Moderate	High	Moderate
Generic availability	Established	Established	Increasing after exclusivity loss
Formulation opportunity	Beads, taste masking, liquids	Broad dosage-form competition	Prodrug and release-system differentiation
Schedule	II	II	II
Main differentiation	Single-isomer amphetamine and dose flexibility	Market breadth	Once-daily prodrug design

DEXEDRINE has a narrower product architecture than the broader mixed-amphetamine market. That limitation creates an opportunity for a company that can improve administration, supply continuity, or release control without adding excessive regulatory complexity.

What is the revenue exposure and commercial value of a DEXEDRINE formulation?

Brand-specific DEXEDRINE revenue is not reliably disclosed as a standalone public metric in the FDA product record or standard regulatory materials. Commercial value is better assessed through market share, prescription volume, average selling price, generic count, shortage history, and dosage-form demand.

Revenue exposure is highest for:

• Sustained-release products with limited supplier competition.
• Pediatric-friendly products with a clear administration benefit.
• Reliable products in shortage-prone stimulant categories.
• Formulations with broad insurance coverage.
• Products supported by a defensible manufacturing patent.

Revenue exposure is lower for an undifferentiated immediate-release tablet because multiple generic suppliers can compete primarily on price.

Key Takeaways

• DEXEDRINE's active ingredient has no meaningful current new-molecule exclusivity.
• Immediate-release tablets offer limited patent and pricing protection.
• Sustained-release multiparticulate capsules provide the strongest excipient-led differentiation opportunity.
• Pediatric taste masking, sprinkle administration, lactose-free tablets, and oral liquids are commercially relevant development areas.
• Excipient changes may support an ANDA when pharmaceutical equivalence and bioequivalence are maintained.
• A materially different release profile, abuse-deterrent system, or novel pediatric product may require a 505(b)(2) application.
• Paragraph IV litigation risk is concentrated in formulation, release-control, manufacturing, and administration patents.
• Controlled-substance quota, API sourcing, and secure distribution are major barriers to commercialization.
• The most valuable asset is a formulation with validated manufacturing, a clear patient benefit, reliable supply, and enforceable patent claims.

FAQs

Can a lactose-free DEXEDRINE generic obtain FDA approval?

Yes. A lactose-free generic may be approved if it meets applicable pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements. The excipient change must not affect safety, efficacy, or product performance.

Is DEXEDRINE SPANSULE suitable for a sprinkle formulation?

A sprinkle formulation may be feasible if the sustained-release beads remain intact, maintain their release profile, and can be administered with an approved food vehicle. The product would require supporting quality and regulatory data.

Can excipients make dextroamphetamine abuse-deterrent?

Excipients can contribute to an abuse-deterrent design, but FDA labeling requires evidence under the agency's abuse-deterrence framework. A polymer or coating alone does not establish an abuse-deterrent claim.

What is the best excipient for extended-release dextroamphetamine?

No single excipient is universally optimal. Ethylcellulose and other controlled-release polymers can support multiparticulate delivery, but performance depends on polymer grade, coating thickness, plasticizer, bead size, curing, and target dissolution profile.

Does a new DEXEDRINE formulation automatically receive patent protection?

No. Patent protection requires claims that are novel, non-obvious, enabled, and properly prosecuted. A new excipient combination may be patentable, but routine substitution of one diluent or lubricant generally offers limited patent strength.

References

1. U.S. Food and Drug Administration. (n.d.). DEXEDRINE and DEXEDRINE SPANSULE prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Drug Enforcement Administration. (n.d.). Drug scheduling and controlled substances. https://www.dea.gov/

3. U.S. Food and Drug Administration. (2019). M13A bioequivalence for immediate-release solid oral dosage forms. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

6. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-generics